Kiniksa Pharmaceuticals International, plc Share Price & Technical Analysis
KNSA · $53.24 (-0.76%)
Healthcare / Drug Manufacturers - Specialty & Generic
$53.24
-0.76%
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-38…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-1% return in May, 11% avg return in past 3 year May month.
26% return in 2026, 41% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | 2% | 9% | 10% | -1% | – | – | – | – | – | – | – | 26% |
| 25 | -2% | 4% | 8% | 22% | 2% | 1% | 10% | 11% | 14% | -5% | 15% | -3% | 78% |
| 24 | 0% | 19% | -8% | -5% | 1% | -3% | 44% | 0% | -6% | -9% | -3% | -10% | 21% |
| 23 | -4% | -10% | -16% | -1% | 29% | 1% | 32% | -9% | 0% | -13% | 5% | 9% | 23% |
| 22 | -5% | -9% | -3% | -7% | -16% | 20% | 2% | 19% | 10% | -12% | 31% | -11% | 20% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Uptrend
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$4.52B
P/E ratio
64.63
52W high
$59.87
52W low
$26.27
Volume
3,83,825
Beta
0.17
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Kiniksa Pharmaceuticals International, plc share price today?
- Kiniksa Pharmaceuticals International, plc (KNSA) last traded around $53.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does KNSA have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for KNSA. Download the app for real-time alerts.
- How can I analyze Kiniksa Pharmaceuticals International, plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.